Phase Ib/II trial of envafolimab, a novel subcutaneous singledomain anti-PD-L1 monoclonal antibody, plus lenvatinib in patients with selected advanced solid tumors

被引：0

作者：

Liu, T. ^{[1
]}

Feng, Y. ^{[1
]}

Xu, X. ^{[1
]}

Ren, X. ^{[2
]}

Jia, J. ^{[3
]}

Pan, H. ^{[4
]}

Wang, B. ^{[5
]}

Wu, B. ^{[6
]}

Cao, X. ^{[7
]}

Liu, J. ^{[8
]}

Yang, Y. ^{[9
]}

Xiao, S. ^{[10
]}

Qin, L. ^{[10
]}

Zhu, D. ^{[10
]}

Xu, S. ^{[10
]}

Huang, W. ^{[10
]}

机构：

[1] Fudan Univ, Zhongshan Hosp, Dept Oncol, Shanghai, Peoples R China

[2] Tianjin Med Univ Canc Inst & Hosp, Dept Biol Therapy, Tianjin, Peoples R China

[3] Dongguan Peoples Hosp, Dept Oncol, Dongguan, Peoples R China

[4] Zhejiang Univ, Sir Run Run Shaw Hosp, Dept Med Oncol, Sch Med, Hangzhou, Peoples R China

[5] 960th Hosp PLA Joint Logist Support Force, Dept Oncol, Jinan, Peoples R China

[6] China Med Univ, Shengjing Hosp, Dept Urol, Shenyang, Peoples R China

[7] Shanxi Med Univ, Hosp 1, Dept Urol, Taiyuan, Peoples R China

[8] Dalian Med Univ, Affiliated Hosp 1, Dept Med Oncol, Dalian, Peoples R China

[9] Kunming Med Univ, Yunnan Canc Hosp, Affiliated Hosp 3, Dept Urol, Kunming, Peoples R China

[10] 3D Med Inc, Dept Clin Dev, Shanghai, Peoples R China

来源：

ANNALS OF ONCOLOGY | 2023年 / 34卷

关键词：

D O I：

10.1016/j.annonc.2023.09.2188

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

1049P

引用

页码：S635 / S635

页数：1

共 50 条

[31] Phase I, open-label, multi-ascending dose trial of avelumab (MSB0010718C), an anti-PD-L1 monoclonal antibody, in Japanese patients with advanced solid tumors.
Shitara, Kohei
Yamada, Yasuhide
Yoh, Kiyotaka
Naito, Yoichi
Iwasa, Satoru
Yamamoto, Noboru
von Heydebreck, Anja
Achiwa, Hiroyuki
Doi, Toshihiko
JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
[32] Bgb-A425, an investigational anti-TIM-3 monoclonal antibody, in combination with tislelizumab, an anti-PD-1 monoclonal antibody, in patients with advanced solid tumors: A phase I/II trial in progress.
Desai, Jayesh
Meniawy, Tarek
Beagle, Brandon
Li, ZheZhen
Mu, Song
Wu, John
Denlinger, Crystal S.
Messersmith, Wells A.
JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
[33] Dostarlimab Anti-PD-1 monoclonal antibody Treatment of advanced solid tumors
Haddley, K.
DRUGS OF THE FUTURE, 2019, 44 (07) : 527 - 534
[34] Phase I study of MK-3475 (anti-PD-1 monoclonal antibody) in patients with advanced solid tumors
Patnaik, Amita
Kang, Soonmo Peter
Tolcher, Anthony W.
Rasco, Drew Warren
Papadopoulos, Kyriakos P.
Beeram, Muralidhar
Drengler, Ronald
Chen, Cong
Smith, Lon
Perez, Crystal
Gergich, Kevin
Lehnert, Manfred
JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
[35] Anti-LAG-3 antibody LBL-007 plus anti-PD-1 antibody toripalimab in advanced nasopharyngeal carcinoma and other solid tumors: an open-label, multicenter, phase Ib/II trial
Chen, Gang
Sun, Dong-Chen
Ba, Yi
Zhang, Ya-Xiong
Zhou, Ting
Zhao, Yuan-Yuan
Zhao, Hong-Yun
Fang, Wen-Feng
Huang, Yan
Wang, Zhen
Deng, Chao
Hu, De-Sheng
Wang, Wei
Lin, Jin-Guan
Li, Gui-Ling
Luo, Su-Xia
Fu, Zhi-Chao
Zhu, Hai-Sheng
Wang, Hui-Li
Cai, Sheng-Li
Kang, Xiao-Qiang
Zhang, Li
Yang, Yun-Peng
JOURNAL OF HEMATOLOGY & ONCOLOGY, 2025, 18 (01)
[36] Model-informed drug development of envafolimab, a subcutaneously injectable PD-L1 antibody, in patients with advanced solid tumors
Cui, Cheng
Wang, Jing
Wang, Chunyang
Xu, Ting
Qin, Lan
Xiao, Shen
Gong, John
Song, Ling
Liu, Dongyang
ONCOLOGIST, 2024, 29 (09): : e1189 - e1200
[37] Phase 1 trial of avelumab (anti-PD-L1) in Japanese patients with advanced solid tumors, including dose expansion in patients with gastric or gastroesophageal junction cancer: the JAVELIN Solid Tumor JPN trial
Toshihiko Doi
Satoru Iwasa
Kei Muro
Taroh Satoh
Shuichi Hironaka
Taito Esaki
Tomohiro Nishina
Hiroki Hara
Nozomu Machida
Yoshito Komatsu
Yasuhiro Shimada
Satoshi Otsu
Shin Shimizu
Morihiro Watanabe
Gastric Cancer, 2019, 22 : 817 - 827
[38] Phase 1 trial of avelumab (anti-PD-L1) in Japanese patients with advanced solid tumors, including dose expansion in patients with gastric or gastroesophageal junction cancer: the JAVELIN Solid Tumor JPN trial
Doi, Toshihiko
Iwasa, Satoru
Muro, Kei
Satoh, Taroh
Hironaka, Shuichi
Esaki, Taito
Nishina, Tomohiro
Hara, Hiroki
Machida, Nozomu
Komatsu, Yoshito
Shimada, Yasuhiro
Otsu, Satoshi
Shimizu, Shin
Watanabe, Morihiro
GASTRIC CANCER, 2019, 22 (04) : 817 - 827
[39] Phase I/Ib Clinical Trial of Sabatolimab, an Anti-TIM-3 Antibody, Alone and in Combination with Spartalizumab, an Anti-PD-1 Antibody, in Advanced Solid Tumors
Curigliano, Giuseppe
Gelderblom, Hans
Mach, Nicolas
Doi, Toshihiko
Tai, David
Forde, Patrick M.
Sarantopoulos, John
Bedard, Philippe L.
Lin, Chia-Chi
Hodi, F. Stephen
Wilgenhof, Sofie
Santoro, Armando
Sabatos-Peyton, Catherine A.
Longmire, Tyler A.
Xyrafas, Alexandros
Sun, Haiying
Gutzwiller, Sabine
Manenti, Luigi
Naing, Aung
CLINICAL CANCER RESEARCH, 2021, 27 (13) : 3620 - 3629
[40] Pharmacokinetic profile and receptor occupancy of avelumab (MSB0010718C), an anti-PD-L1 monoclonal antibody, in a phase I, open-label, dose escalation trial in patients with advanced solid tumors.
Heery, Christopher Ryan
Coyne, Geraldine Helen O'Sullivan
Marte, Jennifer L.
Singh, Harpreet
Cordes, Lisa M.
Madan, Ravi Amrit
Donahue, Renee Nicole
Grenga, Italia
Lepone, Lauren
Neuteboom, Berend
Speit, Isabell
Chin, Kevin M.
Schlom, Jeffrey
Gulley, James L.
JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)

← 1 2 3 4 5 →